Therakos has been granted authorisation by MDR in Europe for the treatment of adverse immunological effects in patients with an insufficient response to corticosteroids.

Summary

DUBLIN, 22 October 2026 — Therakos Development Limited, pioneer worldwide of immunomodulatory therapy administered at the patient's chevet by extracorporal photophérèse (PEC), an announced today qu...